- OncoTree
- PTH
Loading cancer entity…
Loading cancer entity…
Clinical trials
15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05022641 | Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy | completed | N/A | 160 | University of MichiganOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT04299425 | Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy(NIRAF) | completed | N/A | 160 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 13, 2024 |
| clinicaltrials |
| NCT03280264 | Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism | completed | Phase 3 | 18 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT03046524 | Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior | completed | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT01460030 | An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism | completed | Phase 3 | — | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00580320 | Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma | completed | Phase 1 | 17 | Virginia Commonwealth UniversityOTHER | 1 | Aug 18, 2016 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00068497 | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer | completed | N/A | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Aug 27, 2025source: clinicaltrials